GT Biopharma (GTBP) had the highest return in 2012 by a US stock in the Biotechnology Industry, returning 3,044,698,370%.
| ASSET | YEAR | % RETURN |
|---|---|---|
GT Biopharma (GTBP) | 2012 | 3,044,698,370% |
Avita Medical (RCEL) | 2012 | 6,209.94% |
Actinium Pharmaceuticals (ATNM) | 2012 | 1,400% |
Sarepta Therapeutics (SRPT) | 2012 | 469.54% |
Imunon (IMNN) | 2012 | 376.16% |
ACADIA Pharmaceuticals (ACAD) | 2012 | 322.73% |
Sellas Life Sciences (SLS) | 2012 | 296.04% |
MiMedx (MDXG) | 2012 | 233.91% |
Arbutus Biopharma (ABUS) | 2012 | 208.07% |
Regeneron Pharmaceuticals (REGN) | 2012 | 202.73% |
XWELL (XWEL) | 2012 | 189.9% |
Oragenics (OGEN) | 2012 | 161.39% |
Celldex Therapeutics (CLDX) | 2012 | 153.21% |
XTL Biopharmaceuticals Ltd ADR (XTLB) | 2012 | 148.72% |
Grifols SA ADR (GRFS) | 2012 | 143.09% |
Heron Therapeuti (HRTX) | 2012 | 136.96% |
Kazia Therapeutics Ltd ADR (KZIA) | 2012 | 131.67% |
Alnylam Pharmaceuticals (ALNY) | 2012 | 119.09% |
Insmed (INSM) | 2012 | 114.42% |
XOMA (XOMA) | 2012 | 114.29% |
Genmab A-S (GMAB) | 2012 | 114.07% |
Cardiff Oncology (CRDF) | 2012 | 110% |
Sangamo Therapeutics (SGMO) | 2012 | 107.24% |
Propanc Biopharma, Inc Common Stock (PPCB) | 2012 | 102.67% |
Agenus (AGEN) | 2012 | 101.97% |
